1-(2-fluorobenzyl)urea | 296277-54-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-fluorobenzyl)urea
• 英文别名: [(2-Fluorophenyl)methyl]urea；(2-fluorophenyl)methylurea
• CAS: 296277-54-8
• 化学式: C₈H₉FN₂O
• mdl: MFCD01314571
• 分子量: 168.171
• InChiKey: KPJSRAGRCWWCED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-fluorobenzyl)urea 、 2-溴-1-氯-4-氟苯 在 potassium phosphate 、 BrettPhos precatalyst 作用下， 以 叔丁醇 为溶剂， 反应 14.0h， 以75%的产率得到5-fluoro-1-(2-fluorobenzyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
  参考文献：
  名称：

  Regioselective Synthesis of Benzimidazolones via Cascade C–N Coupling of Monosubstituted Ureas

  摘要：

  A direct method for the regioselective construction of benzimidazolones is reported wherein a single palladium catalyst is employed to couple monosubstituted urea substrates with differentially substituted 1,2-dihaloaromatic systems. In this method, the catalyst is able to promote a cascade of two discrete chemoselective C-N bond-forming processes that allows the highly selective and predictable formation of complex heterocycles from simple, readily available starting materials.

  DOI：

  10.1021/ol501531q
• 作为产物：
  描述：

  potassium cyanate 、 2-氟苄胺 在 盐酸 作用下， 以 水 为溶剂， 反应 3.0h， 以53%的产率得到1-(2-fluorobenzyl)urea
  参考文献：
  名称：

  Regioselective Synthesis of Benzimidazolones via Cascade C–N Coupling of Monosubstituted Ureas

  摘要：

  A direct method for the regioselective construction of benzimidazolones is reported wherein a single palladium catalyst is employed to couple monosubstituted urea substrates with differentially substituted 1,2-dihaloaromatic systems. In this method, the catalyst is able to promote a cascade of two discrete chemoselective C-N bond-forming processes that allows the highly selective and predictable formation of complex heterocycles from simple, readily available starting materials.

  DOI：

  10.1021/ol501531q

文献信息

• [EN] NOVEL CATHEPSIN C INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE LA CATHEPSINE C ET LEUR UTILISATION
  申请人：GLAXO GROUP LTD

  公开号：WO2009026197A1

  公开（公告）日：2009-02-26

  The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.

  这项发明涉及到符合以下式（I）的化合物，其中R1、R2a、R2b、R2c、R3和n的定义如下，并且其药用盐。它们是半胱氨酸蛋白酶C抑制剂，可用于治疗由半胱氨酸蛋白酶C酶介导的疾病，如慢性阻塞性肺病。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• Novel quinazoline derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20070010671A1

  公开（公告）日：2007-01-11

  The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(1)，并作为MCH受体拮抗剂。这些化合物在制药组合物中的使用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴食障碍（包括贪食症、厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆）、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。
• In vitro method to detect allergic reactions to low molecular weight chemicals
  申请人：Monsanto Company

  公开号：EP0265411A2

  公开（公告）日：1988-04-27

  This invention relates to the use of IgE sensitized basophiles and mast cells in in vitro tests to determine histamine release when challenged with small molecular weight chemical haptens conjugated to protein, e.g., human serum albumin.

  本发明涉及在体外试验中使用对 IgE 敏感的嗜碱性细胞和肥大细胞，以确定它们在受到与蛋白质（如人血清白蛋白）共轭的小分子量化学触杀素挑战时的组胺释放量。
• [EN] N'-HETEROCYCLYL-N-BENZOFURANYL UREA DERIVATIVES AND THEIR ANALOGS AS ACAT INHIBITORS<br/>[FR] DERIVES D'UREE N'-HETEROCYCLYL-N-BENZOFURANYLE ET LEURS ANALOGUES, UTILISES COMME INHIBITEURS DE L'ACAT
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1994026738A1

  公开（公告）日：1994-11-24

  (EN) This invention relates to new urea derivatives having an inhibitory activity against acyl-CoA:cholesterol acyltransferase enzyme and represented by general formula (I), wherein R1 is a heterocyclic group which may be substituted with lower alkyl, etc., R2 is lower alkyl, etc., R3 is hydrogen, lower alkyl or aryl which may be substituted with halogen, etc., R4 is hydrogen, halogen, lower alkyl, lower alkoxy or acyl which may be substituted with halogen, R5 is aryl, etc., A is a single bond, etc., and X is O, etc., provided that at least one of unsubstituted or substituted aryl for R3, R4 and R5 is aryl except phenyl or substituted aryl, and pharmaceutically acceptable salts thereof, to processes for the preparation thereof and to a pharmaceutical composition comprising the same.(FR) L'invention se rapporte à de nouveaux dérivés d'urée, qui possèdent un effet inhibiteur contre l'enzyme acyl-CoA:cholestérol acyltransférase et qui sont représentés par la formule générale (I), où R1 représente un groupe hétérocyclique qui peut être substitué par alkyle inférieur, etc., R2 représente alkyle inférieur, etc., R3 représente hydrogène, alkyle inférieur ou aryle qui peuvent être substitués par halogène, etc., R4 représente hydrogène, halogène, alkyle inférieur, alcoxy inférieur ou acyle qui peuvent être substitués par halogène, R5 représente aryle, etc., A représente une liaison simple, etc., et X représente O, etc., à condition qu'au moins l'un des aryles insubstitués ou substitués que représentent R3, R4 et R5 soit un aryle autre que phényle ou aryle substitué, ainsi qu'à des sels pharmaceutiquement acceptables de ces dérivés, à des proécés pour leur préparation et à une composition pharmaceutique qui les contient.